Earnings Call Insights: Coloplast A/S (OTCPK:CLPBF) Q1 2025 CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations.

Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2023/24. In addition, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Thursday, JPMorgan analyst Anchal Verma upgraded the stock rating of Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) from Underweight to Neutral, setting a price target of DKK700.00.

Investing.com -- Shares of Coloplast (CSE:COLOb) climbed 3.5% as the medical device company reported first-quarter revenue in line with consensus expectations and earnings per share (EPS ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The global Urinary Incontinence Devices Market, valued at US$3.82 billion in 2023, is forecasted to grow at a robust CAGR of 11.2%, ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...